Navigation Links
DoseCue(TM) Presents Positive Study Results at BioTech 2009
Date:11/16/2009

PHILADELPHIA, Nov. 16 /PRNewswire/ -- DoseCue, LLC announced this week that medication containers equipped with their automatic dose-time reminder devices significantly increase compliance, or adherence, according to results from a recent study.

The data, which were presented at BioTech 2009 in Philadelphia, showed that DoseCue electronic devices significantly improved patient compliance with oral-dose medications by 9.1%, without adding steps or changing the patient's dose-taking routine. In addition, overall compliance averaged 97.1% in the Study Group in Phase 2.

"This represents an important 'first'," stated DoseCue CEO, Mark Burrows. "The DoseCue trial is the first of its kind to achieve a statistically significant improvement in compliance using this one-of-a-kind, patented technology," he added, noting 95% Confidence Interval.

DoseCue's patented technology is integrated directly into manufacturers' current containers during filling and issues automatic reminder cues to patients when a medication needs to be dosed and signals when the dose has been taken. Electronics are integrated into the medication container itself, not the closure, to avoid mix-up and help differentiate the product.

The DoseCue study was conducted at a retail pharmacy to determine if patient compliance improved when oral-dose medications were dispensed in a DoseCue-equipped container. Thirty-five (35) patients were enrolled and randomized into either a Control or Study Group. All patients used an inactive container for Month 1 (Phase 1) which, unknown to participants, automatically logged date and time of open/close events, after which half were crossed-over to a container which also cued at dose time (Study Group). Remaining patients continued use of the inactive container (Control Group). Twenty-four (24) patients completed the study.

"We know the costs of non-compliance are high," said Burrows. "With DoseCue, there's no guesswork and compliance rates improve, resulting in better disease management, increased sales, and lower costs to the healthcare system."

DoseCue, LLC is a medication compliance company that integrates electronic dose-time reminder cues into manufacturers' existing factory-filled containers. These containers are clinically proven to increase compliance and remove the burden on patients to remember to take their oral-dose medication as prescribed by their physician.

www.dosecue.com

SOURCE DoseCue, LLC


'/>"/>
SOURCE DoseCue, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Frontiers in Optics presents scientific advancements
2. New book presents successful strategies for probing genetic variation
3. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
4. New book presents methods to poke and prod individual molecules
5. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
6. Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings
7. ICS presents prestigious Digby McLaren Medal to Cincinnatis Carl Brett
8. Penn presents inaugural symposium on applied mathematics and computational science
9. Soil Science Society of America presents 2008 fellows
10. Soil Science Society of America presents awards in Houston
11. Arbor Vita presents new data on cancer diagnostic at EUrogin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
Breaking Biology Technology: